The Pharmasyntez Group once again proved its exceptional role in the global pharmaceutical industry by presenting cutting-edge drugs at the largest international exhibition, CPHI & PMEC 2025, in Shanghai.

As the sole representative of the Russian pharmaceutical sector, Pharmasyntez underscored its status and importance in the world of Big Pharma.

At Pharmasyntez’s impressive booth, hundreds of partners from around the world discussed strategic collaboration opportunities, innovative developments, and prospects for joint projects. This platform serves as a powerful springboard for strengthening Russia’s position in global pharmaceuticals and showcasing our advanced technologies.

Pharmasyntez demonstrated its achievements: For the first time in Russia — Vamotinib, a fully domestic third-generation tyrosine kinase inhibitor designed to combat resistant chronic myeloid leukemia. The unique anti-adhesion drug Seroguard — an innovative solution with no global analogues, created to enhance the safety and efficacy of surgical interventions in gynecology and abdominal surgery.

CPHI & PMEC is an arena for challenging global giants, confirming our leadership, and aspiring to become a key player on the international pharmaceutical map.